Life Sciences Business Insurance | Cory Washington & Co.

Life Sciences Business Insurance

Life sciences insurance coordinates high-severity products and clinical-trial liability with professional and management liability for biotech, pharma, device, diagnostics, and research firms across the lifecycle.

Industry Coverage

From Lab Bench to Market, Complex Risk Follows Every Breakthrough.

Protecting biotech, pharma, device, and research companies across the lifecycle

If you run a life sciences company — biotechnology, pharmaceutical, medical device, diagnostics, or research — you carry one of the most complex risk profiles in the economy, because your exposure spans product development, human clinical trials, manufacturing, intellectual property, and the professional judgment behind every result. Your signature risk is not a single peril but a cluster: high-severity products liability, clinical-trial and human-subject liability, professional liability, and management liability, all shifting as you move from an early-stage venture-backed startup toward a commercial-stage manufacturer. A trial injury, a product defect, a funding dispute, or a recall can each threaten years of research and investment. This class draws on manufacturing insurance foundations but reaches well beyond them, and it has to be built to your lifecycle stage rather than a generic template.

Properly structured coverage protects your company, your science, your investors, and the patients and subjects downstream.

The Life Sciences Company's Signature Exposures

Your defining exposure is products liability at the severe end of the scale — an implant, drug, diagnostic, or biologic that injures a patient drives catastrophic bodily-injury, wrongful-death, and multi-plaintiff litigation. Running alongside it is clinical-trial and human-subject liability: injury to research participants during your studies, governed by informed consent and institutional review board (IRB) oversight and frequently required by protocol and by law. Professional and technology E&O covers errors in research, testing, data, and diagnostic products, while management liability, directors and officers coverage above all, protects the board and executives whose governance and funding decisions carry outsized exposure for a venture-funded company. Intellectual-property disputes, recall and contamination costs, and contract-manufacturing dependencies round out a profile where regulatory discipline is inseparable from insurability.

Key Risks in Life Sciences Operations

You face exposure related to:

  • A drug, device, diagnostic, or biologic that injures a patient or trial subject
  • Injury to human research subjects during a domestic or foreign clinical trial
  • An FDA recall or contamination event requiring market withdrawal
  • Errors in research, testing, data, or software-driven and diagnostic products
  • Intellectual-property, patent, and licensing disputes over the pipeline
  • Investor, governance, and securities exposure for venture-funded companies
  • Contract-manufacturing (CMO) and supply-chain defects flowing through to the company

The high-severity product injury and the clinical-trial liability are what most define the company.

Core Coverages for Life Sciences Companies

A properly built life sciences program typically includes:

Products & Completed Operations Liability — Covers injury or damage alleged from a device, drug, diagnostic, or biologic after it reaches a patient, written at high limits because severity is among the worst of any class.

Clinical Trial Liability — Covers injury to human research subjects during studies, often required by protocol and by law and tied to IRB and informed-consent requirements.

Professional / Technology E&O — Covers errors in research, testing, data, algorithms, and software-driven or diagnostic products.

Directors & Officers Liability — Protects boards and executives over governance, funding, and securities exposure — critical for venture-backed and pre-IPO companies.

Product Recall & Contamination — Responds to the withdrawal, notification, and replacement costs of a defective or contaminated product, including an FDA recall campaign.

Commercial Property, Cargo & Equipment — Covers labs, clean rooms, specialized instruments, inventory, and temperature-sensitive shipments.

Cyber & Privacy — Protects research data, protected health information, and connected or software-based medical products.

Workers' Compensation — Provides legally required coverage for employees across labs, production, and field operations.

Umbrella / Excess Liability — Adds the high excess limits that product and trial severity demand above the primary program.

What's Commonly Overlooked

Common weak spots in life sciences coverage:

  • Product-liability and excess limits too low for a high-severity injury or multi-plaintiff claim
  • No distinct clinical-trial liability where a protocol or regulator requires it
  • Management liability (D&O) under-built for a venture-funded or pre-IPO company
  • Recall and contamination limits inadequate for an FDA campaign
  • Contract-manufacturing and distributor indemnity assumed but never reviewed against the policy

The gap that hurts most is inadequate product-liability and excess limits for a high-severity patient or trial injury.

Claim Scenarios

  • A marketed drug is alleged to cause patient harm and multi-plaintiff litigation follows, and claims-made product liability responds only if the policy is in force when the claims arrive and limits match the exposure
  • A participant is injured during a clinical trial, and clinical-trial liability covers it, while a general liability policy excludes bodily injury from investigational products
  • A diagnostic returns a false result that leads to a wrong treatment, and professional or product liability responds depending on how the test is regulated, so the form must name diagnostics expressly
  • The FDA orders a recall and notification and replacement costs mount, a loss that product liability excludes, so only a product-recall policy pays and typically with its own sublimit
  • Investors sue the board after a failed trial collapses the valuation, and directors and officers coverage responds, though an exclusion for claims related to prior known circumstances can remove it

A single claim like these can be catastrophic, and a product or trial-injury claim can reach well into eight figures.

Regulatory & Compliance Context

The U.S. Food and Drug Administration governs the entire lifecycle — investigational new drug (IND) and investigational device exemption (IDE) applications before trials, the market pathways (NDA and BLA for drugs and biologics; 510(k), PMA, and De Novo for devices), and post-market surveillance and adverse-event reporting afterward. Human clinical research is further governed by Good Clinical Practice, the Common Rule for the protection of human subjects, and institutional review board (IRB) oversight, with informed consent required throughout. Device and diagnostic makers operate under FDA's Quality Management System Regulation (21 CFR 820), which took effect February 2, 2026 and incorporates ISO 13485 by reference, and companies selling in Europe must additionally meet the EU Medical Device Regulation or the European Medicines Agency's requirements. Underwriters expect this framework in place, and a clean regulatory and quality record is central to placement.

Why Proper Placement Matters

Lifecycle stage and product class are the biggest drivers — a pre-clinical, venture-backed startup, a company running first-in-human trials, and a commercial-stage manufacturer present entirely different risks and belong on different programs. Underwriters weigh your pipeline and its end use, trial phase and geography, FDA and foreign regulatory status, intellectual-property position, funding structure, and contract and manufacturing arrangements. Most life sciences risk is written in the excess and surplus lines (E&S) and specialty markets, where carriers can tailor high limits, carve clinical-trial terms, and underwrite emerging science. Presenting a disciplined regulatory posture, clear trial design, and documented quality and governance controls is what opens appetite and improves terms for an inherently high-severity class.

Our Approach

At Cory Washington & Co., we structure life sciences programs around your lifecycle stage, your pipeline, and your contracts — coordinating products, clinical-trial, professional, and management liability so protection matches real exposure rather than a checklist, and sizing limits to the severity of what you develop. We access the specialty and E&S markets built for emerging and complex life sciences risk and explain every trade-off clearly. We also insure related businesses, including medical device manufacturers, pharmaceutical wholesalers, and medical laboratories.

From lab bench to market, your risk shifts at every stage — we build coverage that moves with the science rather than lagging behind it.

Life Sciences Business Insurance, written around what you actually do.

Tell us how your business operates, and a member of our team will review it personally and walk you through what your coverage needs to address.

Free coverage checklist

See the coverages a life sciences business may carry — core, prevalent, and situational — plus the gap most often missed, in the Life Sciences Business Coverage Checklist.

Already know what you need? Complete the Life Sciences Business application online or download the PDF.

Frequently Asked Questions

What insurance does a life sciences business need?

The foundation for a life sciences business is usually Products & Completed Operations Liability, Clinical Trial Liability, and Professional / Technology E&O. Depending on the operation, Directors & Officers Liability; Product Recall & Contamination; and Commercial Property, Cargo & Equipment round out the program. Your defining exposure is products liability at the severe end of the scale — an implant, drug, diagnostic, or biologic that injures a patient drives catastrophic bodily-injury, wrongful-death, and multi-plaintiff litigation.

What insurance gaps are most often overlooked for a life sciences business?

Watch for product-liability and excess limits too low for a high-severity injury or multi-plaintiff claim, and for no distinct clinical-trial liability where a protocol or regulator requires it. The gap that hurts most is inadequate product-liability and excess limits for a high-severity patient or trial injury.

What regulations affect insurance for a life sciences business?

The U.S. Food and Drug Administration governs the entire lifecycle — investigational new drug (IND) and investigational device exemption (IDE) applications before trials, the market pathways (NDA and BLA for drugs and biologics; 510(k), PMA, and De Novo for devices), and post-market surveillance and adverse-event reporting afterward.

What do underwriters look at when insuring a life sciences business?

Lifecycle stage and product class are the biggest drivers — a pre-clinical, venture-backed startup, a company running first-in-human trials, and a commercial-stage manufacturer present entirely different risks and belong on different programs.

What are common insurance claims for a life sciences business?

Common examples: A marketed drug is alleged to cause patient harm and multi-plaintiff litigation follows, and claims-made product liability responds only if the policy is in force when the claims arrive and limits match the exposure. A participant is injured during a clinical trial, and clinical-trial liability covers it, while a general liability policy excludes bodily injury from investigational products. A diagnostic returns a false result that leads to a wrong treatment, and professional or product liability responds depending on how the test is regulated, so the form must name diagnostics expressly.

What if another agency has already declined or non-renewed my coverage?

Difficult, specialty, and previously declined placements are a core part of our work. We access excess & surplus (E&S) and specialty markets that many generalist agencies cannot, and we explain the trade-offs clearly so you can decide with confidence.

Related Industries

Manufacturing Business Insurance · All Manufacturing & Wholesale industries →

Available in all 50 states. See how requirements differ in California, Texas, Florida, New York, or choose your state.

All insurance descriptions on this website are provided by Cory Washington & Co. LLC strictly for general informational purposes. They are not intended to be, and should not be relied upon as, legal, financial, or insurance advice. The information presented is general in nature and does not guarantee the availability, terms, conditions, or scope of any insurance coverage. Actual coverage is determined solely by the specific policy language issued by the insurer and remains subject to underwriting approval. Nothing on this website creates or implies an agent-client relationship, binds coverage, or alters any existing policy. Cory Washington & Co. LLC expressly disclaims any liability for actions taken, or not taken, based on the content provided here. For advice regarding your particular situation, please consult directly with a licensed insurance professional at Cory Washington & Co. LLC or another qualified insurance professional, and always review your policy documents in full.

Protect What You’ve Built

When everything you’ve built is on the line, a quote isn’t enough. Tell us about your business and receive a considered assessment — not a form letter.